Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy

@article{Ruggeri2018CostEffectivenessAO,
  title={Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy},
  author={Matteo Ruggeri and Michele Basile and C Drago and Francesca Romana Rolli and Americo Cicchetti},
  journal={PharmacoEconomics},
  year={2018},
  volume={36},
  pages={625-636}
}
BackgroundUntil very recently the only therapeutic alternative for the management of patients affected by gout/hyperuricemia that did not respond to a first-line treatment based on allopurinol alone or who cannot tolerate allopurinol was febuxostat, a xanthine oxidase non-purine-selective inhibitor. Lately, however, a new therapeutic alternative has become available for the management of this pathology: lesinurad, a urate transporter inhibitor.ObjectiveTo objective of this study was to evaluate… CONTINUE READING
2
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-2 OF 2 CITATIONS

Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients

María Presa, Fernando Pérez-Ruiz, Itziar Oyagüez
  • Clinical Rheumatology
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach.

  • Medical decision making : an international journal of the Society for Medical Decision Making
  • 1985
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Nomenclatore tariffario dell’assistenza specialistica ambulatoriale. http://www.salute.gov.it/portale/temi/ p2_6.jsp?id=1767&area=programmazioneSanitariaLea&menu= lea

Ministero della Salute
  • Accessed Apr
  • 2016
VIEW 1 EXCERPT

Prontuario farmaceutico Nazionale. http://www.agenziafarmaco.gov.it/it/content/ prontuario-farmaceutico-nazionale

  • Accessed Apr
  • 2016
VIEW 1 EXCERPT

HBeAg ? and HBeAg hepatitis B patients treated with tenofovir df showed no relationship between virologic breakthrough and emergence of genotypic changes in HBV polymerase

A Snow-Lampart, BJ Chappell, M Curtis
  • Hepatology
  • 2009
VIEW 2 EXCERPTS